Medicare Part B: Immunoglobulin Therapy
Customize your policy alerts
Sign up for all MVP Health Care policy alerts
Know when MVP Health Care releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and Medicare Part B coverage for intravenous and subcutaneous immune globulin therapy, including specified billing codes, coverage criteria, authorization periods, vendor requirements, and continuation documentation. It primarily applies to Medicare members receiving therapy for primary immunodeficiency.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.